Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 8,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Genomic Health, Inc. (NASDAQ GHDX) traded up 0.43% during midday trading on Wednesday, hitting $30.52. 67,023 shares of the stock were exchanged. Genomic Health, Inc. has a 12 month low of $25.66 and a 12 month high of $33.97. The firm’s 50-day moving average is $32.54 and its 200-day moving average is $31.04. The stock’s market cap is $1.05 billion.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $86.08 million. During the same period last year, the business earned ($0.18) EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities research analysts predict that Genomic Health, Inc. will post $0.01 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/09/james-j-vaughn-sells-8000-shares-of-genomic-health-inc-ghdx-stock.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Genomic Health during the fourth quarter valued at about $575,000. Norges Bank acquired a new position in shares of Genomic Health during the fourth quarter valued at about $4,546,000. Teachers Advisors LLC boosted its position in shares of Genomic Health by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock valued at $935,000 after buying an additional 1,838 shares during the period. Highbridge Capital Management LLC acquired a new position in shares of Genomic Health during the fourth quarter valued at about $274,000. Finally, First National Bank of Omaha boosted its position in shares of Genomic Health by 21.5% in the first quarter. First National Bank of Omaha now owns 25,740 shares of the medical research company’s stock valued at $811,000 after buying an additional 4,553 shares during the period. 89.53% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on GHDX shares. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 18th. Raymond James Financial, Inc. reiterated a “market perform” rating on shares of Genomic Health in a research note on Wednesday, May 3rd. They noted that the move was a valuation call. BidaskClub lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $31.00 target price on shares of Genomic Health in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $32.43.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.